Melanoma Clinical Trials in Cleveland

Showing 61-80 of 152 trials

COMPLETED< 1 mile

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

NCT05079113

To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.

Stage III MelanomaStage IV Cutaneous Melanoma

Case Comprehensive Cancer Center73 participantsStarted Oct 2019

Cleveland, Ohio, United States

COMPLETEDPHASE1< 1 mile

Study of the CD40 Agonistic Monoclonal Antibody APX005M

NCT02482168

This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.

CancerNSCLCMelanoma+3 more

Apexigen America, Inc.43 participantsStarted May 2015

Duarte, California, United States • Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPHASE151 miles

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

NCT03864042

This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme probe substrates using a probe cocktail, on an organic anion-transporting polypeptide/breast cancer resistance protein (OATP/BCRP) substrate using rosuvastatin and on a CYP2B6 substrate using bupropion. The effect of multiple oral doses of the moderate cytochrome P450 (CYP) inhibitor modafinil on encorafenib in combination with binimetinib will also be assessed. The study will have 2 treatment phases, a drug-drug interaction (DDI) phase followed by a post-DDI phase.

Advanced Solid TumorsMetastatic Melanoma

Pfizer56 participantsStarted Jan 2018

Orange, California, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +26 more locations

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Melanoma Trials in Other Cities

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

Other Conditions in Cleveland